SCHEMBL3123752

SCHEMBL3123752

CCN1C(=O)S/C(=C\c2ccc(-c3cccc(OC)c3)o2)C1=S

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 1/20 0.59
▸ MAP3K5 Q99683 3/20 0.49
▸ MEN1 O00255 5/20 0.49
▸ KMT2A Q03164 5/20 0.49
▸ POLB P06746 5/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ L3MBTL1 Q9Y468 3/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ GPR55 Q9Y2T6 1/20 0.49
▸ ITGB2 P05107 2/20 0.48
▸ ITGAM P11215 2/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ TDP1 Q9NUW8 2/20 0.45
▸ STAT3 P40763 1/20 0.45
▸ MAPT P10636 3/20 0.44
▸ APEX1 P27695 1/20 0.44
▸ PTPN22 Q9Y2R2 3/20 0.44
▸ PKM P14618 2/20 0.44
▸ PTPN7 P35236 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3123756 1.00 PIK3CG (0.59) PIK3CGMAP3K5MEN1KMT2APOLB
SCHEMBL3123759 1.00 PIK3CG (0.59) PIK3CGMAP3K5MEN1KMT2APOLB
SCHEMBL3135575 0.86 MAP3K5 (0.64) PIK3CGMAP3K5MEN1KMT2APOLB
SCHEMBL3135562 0.86 MAP3K5 (0.64) PIK3CGMAP3K5MEN1KMT2APOLB
SCHEMBL3135568 0.86 MAP3K5 (0.64) PIK3CGMAP3K5MEN1KMT2APOLB
SCHEMBL3135564 0.86 MAPT (0.60) MAP3K5MEN1KMT2APOLBRAB9A
SCHEMBL3131284 0.86 MEN1 (0.48) MAP3K5MEN1KMT2APOLBRAB9A
SCHEMBL3131271 0.86 MEN1 (0.48) MAP3K5MEN1KMT2APOLBRAB9A
SCHEMBL3131279 0.86 MEN1 (0.48) MAP3K5MEN1KMT2APOLBRAB9A
SCHEMBL3135572 0.86 MAPT (0.60) MAP3K5MEN1KMT2APOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 — — US claimed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 — — WO claimed
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 — — US disclosed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses MAVS, LAMP1, HAVCR2 PIK3CG 4355/4885MAP3K5 3869/4885MEN1 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback